Certified by Founder
Lodge
Immunai
start up
United States
- New York, NY
- 28/10/2021
- Series B
- $215,000,000
Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
- Industry Biotechnology Research
- Website https://www.immunai.com/
- LinkedIn https://www.linkedin.com/company/immunai/
SpeedLabs | $6,500,000 | (Jun 2, 2026)
Invertix | $1,977,831 | (Jun 2, 2026)
XCENA | $135,000,000 | (Jun 2, 2026)
Gray Swan | $40,000,000 | (Jun 2, 2026)
Human Archive (YC W26) | $8,200,000 | (Jun 2, 2026)
Countable Labs | $26,000,000 | (May 29, 2026)
Rep AI | $6,200,000 | (May 29, 2026)
Psilera | $8,800,000 | (May 29, 2026)
MokN | $15,000,000 | (May 29, 2026)
Crimson | $2,500,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)